Annual banned-substance review: analytical approaches in human sports drug testing / Mario Thevis, Tiia Kuuranne, Hans Geyer
- Drug Testing and Analysis 14 (2022) 11 November
- PMID: 36369629
- DOI: 10.1002/dta.3408
Contents:
- Introduction
- Anabolic Agent
- Anabolic-androgenic steroids (AASs)
- Initial testing procedures (ITP): Comprehensive screening, metabolism studies
- Other anabolic agents
- Steroid profiling in urine and blood
- Confirmatory testing procedures – IRMS
- Peptide Hormones, Growth Factors, Related Substances, and Mimetics
- Erythropoietin-receptor agonists
- Growth hormone (GH), its fragments and releasing factors
- β2‐Agonists, Hormone and Metablolic Modulators, and diuretics
- Stimulants, Glucocorticoids, and Cannabinoids
- Manipulation of blood and blood components
- Chemical and Physical Manipulation and Gene Doping
- Conclusion
Abstract
Also in 2021/2022, considerable efforts were invested into advancing human sports drug testing programs, recognizing and taking into account existing as well as emerging challenges in anti-doping, especially with regard to substances and methods of doping specified in the World Anti-Doping Agency's 2022 Prohibited List. In this edition of the annual banned-substance review, literature on recent developments published between October 2021 and September 2022 is summarized and discussed. Focus is put particularly on enhanced analytical approaches and complementary testing options in human doping controls, appreciating the exigence and mission in anti-doping and, equally, the contemporary “new normal” considering, for example, the athlete's exposome versus analytical sensitivity and applicable anti-doping regulations for result interpretation and management.
